Stock Track | Abivax Plummets 5.33% Intraday as CEO Downplays Sale Talk and Eyes Capital Raise

Stock Track03-25

Abivax S.A. (ABVX) shares plummeted 5.33% during intraday trading on Tuesday.

The decline follows news that the company's CEO has downplayed recent takeover speculation, indicating the firm is not under pressure to sell. Instead, management is focused on strengthening its financial position and is likely to pursue a mix of equity and debt financing after the readout of critical Phase 3 trial data for its lead drug candidate, obefazimod, expected in the late second quarter of 2026. This potential capital raise, aimed at funding operations toward profitability, may have raised concerns among investors about potential dilution of existing shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100070762?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 02:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100070762","market":"sg","top_or_hot":-1,"title":"Stock Track | Abivax Plummets 5.33% Intraday as CEO Downplays Sale Talk and Eyes Capital Raise","media":"Stock Track","content":"<p>Abivax S.A. (ABVX) shares plummeted 5.33% during intraday trading on Tuesday.</p><p>The decline follows news that the company's CEO has downplayed recent takeover speculation, indicating the firm is not under pressure to sell. Instead, management is focused on strengthening its financial position and is likely to pursue a mix of equity and debt financing after the readout of critical Phase 3 trial data for its lead drug candidate, obefazimod, expected in the late second quarter of 2026. This potential capital raise, aimed at funding operations toward profitability, may have raised concerns among investors about potential dilution of existing shares.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Abivax Plummets 5.33% Intraday as CEO Downplays Sale Talk and Eyes Capital Raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Abivax Plummets 5.33% Intraday as CEO Downplays Sale Talk and Eyes Capital Raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-25 02:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Abivax S.A. (ABVX) shares plummeted 5.33% during intraday trading on Tuesday.</p><p>The decline follows news that the company's CEO has downplayed recent takeover speculation, indicating the firm is not under pressure to sell. Instead, management is focused on strengthening its financial position and is likely to pursue a mix of equity and debt financing after the readout of critical Phase 3 trial data for its lead drug candidate, obefazimod, expected in the late second quarter of 2026. This potential capital raise, aimed at funding operations toward profitability, may have raised concerns among investors about potential dilution of existing shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1100070762","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100070762","pubTimestamp":1774375476,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Abivax S.A. (ABVX) shares plummeted 5.33% during intraday trading on Tuesday.The decline follows news that the company's CEO has downplayed recent takeover speculation, indicating the firm is not...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"个股追踪|Abivax盘中暴跌5.33%CEO淡化出售言论着眼于融资","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"Abivax S.A. (ABVX) shares plummeted 5.33% during intraday trading on Tuesday.The decline follows news that the company's CEO has downplayed recent takeover speculation, indicating the firm is not under pressure to sell. Instead, management is focused on strengthening its financial position and is likely to pursue a mix of equity and debt financing after the readout of critical Phase 3 trial data for its lead drug candidate, obefazimod, expected in the late second quarter of 2026. This potential capital raise, aimed at funding operations toward profitability, may have raised concerns among investors about potential dilution of existing shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100070762","isCrawlerRequest":true}